CAS No.64-86-8,Colchicine Suppliers

Products Categories

Pharmaceutical (166)
Plant Extract (68)
Others (59)
Organic Chemicals (28)
Reagent (13)
Materials (4)
(2)

Basic Information

Molecular Structure:
CAS No.:	64-86-8
Name:	Colchicine
Article Data:	23

Formula:	C₂₂H₂₅NO₆
Molecular Weight:	399.444
Synonyms:	Acetamide,N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)-, (S)-;Colchicine (8CI);(-)-Colchicine;(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide;Colchineos;Colchisol;Colcin;Colsaloid;Condylon;NSC 757;
EINECS:	200-598-5
Density:	1.25 g/cm³
Melting Point:	150-160 °C (dec.)(lit.)
Boiling Point:	726 °C at 760 mmHg
Flash Point:	392.9 °C
Solubility:	45 g/L (20 °C) in water
Appearance:	Yellow solid
Hazard Symbols:	T, T+
Risk Codes:	26/28
Safety:	13-45
Transport Information:	UN 1544 6.1/PG 1
PSA:	83.09000
LogP:	3.26250

Synthetic route

: 108-24-7
acetic anhydride

: 186374-95-8
(S)-tert-butyl N-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalene-7-yl)carbamate

: 64-86-8
colchicine

Conditions

Conditions	Yield
Stage #1: (S)-tert-butyl N-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalene-7-yl)carbamate With hydrogenchloride In diethyl ether at 20℃; for 1h; Stage #2: acetic anhydride With dmap; triethylamine In diethyl ether at 25℃; for 10h;	98%

: methoxymagnesium bromide

: 10-demethoxy-10-tosylcolchicine

: 64-86-8
colchicine

Conditions

Conditions	Yield
In tetrahydrofuran for 5h;	85%

: C22H27NO7

: 64-86-8
colchicine

Conditions

Conditions	Yield
With N,N-dimethyl-ethanamine; trimethylsilyl trifluoromethanesulfonate In dichloromethane at 20℃; for 12h; Inert atmosphere;	81%
With N,N-dimethyl-ethanamine; trimethylsilyl trifluoromethanesulfonate In dichloromethane	81%
With trimethylsilyl trifluoromethanesulfonate; triethylamine In dichloromethane at 20℃; for 2h;	75%

: 109-88-6, 16436-83-2, 16436-85-4
magnesium methanolate

: 10-demethoxy-10-tosylcolchicine

: 64-86-8
colchicine

Conditions

Conditions	Yield
In methanol	78%

: 186581-53-3, 908094-01-9
diazomethane

: 60-29-7
diethyl ether

: 67-66-3
chloroform

: 477-27-0, 1990-46-1
colchiceine

A: 64-86-8
colchicine

B: 518-12-7
(7S)-isocolchicine

...Expand

: 186581-53-3, 908094-01-9
diazomethane

: 477-27-0, 1990-46-1
colchiceine

A: 64-86-8
colchicine

B: 518-12-7
(7S)-isocolchicine

Conditions

Conditions	Yield
With diethyl ether; chloroform

...Expand

: 186581-53-3, 908094-01-9
diazomethane

: 33530-04-0
2,10-didemethylcolchicine

A: 64-86-8
colchicine

B: 7336-36-9
2-demethylcolchicine

C: 518-12-7
(7S)-isocolchicine

D: 142713-50-6
2-demethylisocolchicine

Conditions

Conditions	Yield
In diethyl ether; chloroform

...Expand

: 133946-40-4
<1-3H>-3-phenylpropanal

: 64-86-8
colchicine

Conditions

Conditions	Yield
Colchicum byzantinum biosynthesis;

: 4469-06-1
<3-14C>-cinnamic acid

: 64-86-8
colchicine

Conditions

Conditions	Yield
Colchicum byzantinum biosynthesis;

: 3476-50-4
deacetylcolchicine

: 108-24-7
acetic anhydride

: 64-86-8
colchicine

Conditions

Conditions	Yield
With sodium hydrogencarbonate In chloroform; water for 2.5h;
Acetylation;

Raw Materials

53560-26-2

3476-50-4

477-27-0

4521-61-3

60-29-7

67-66-3

33530-04-0

108-24-7

Downstream Products

518-11-6

477-30-5

Total:238 Page 1 of 7 1 2 3 4 5 6 …7 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 64-86-8

Chemistry

IUPAC: N-[(7S)-1,2,3,10-Tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
Molecular Formula:C₂₂H₂₅NO₆
Molecular Weight:399.44
EINECS:200-598-5
Melting Point:150-160 °C (dec.)(lit.)
Solubility: H₂O: 10 mg/mL
Form:Powder
Color:White to yellow with a green cast
Water Solubility:45 g/L (20 °C)
Classification Code: Agricultural Chemical; Antimitotic Agents; Antirheumatic Agents; Drug / Therapeutic Agent; Gout suppressants; Human Data; Mitosis Modulators; Mutation data; Reproductive Effect; Skin / Eye Irritant; Suppressant [gout]; Tubulin Modulators
Index of Refraction: 1.584
Molar Refractivity: 106.6 cm³
Molar Volume: 318.1 cm3
Surface Tension: 50.5 dyne/cm
Density: 1.25 g/cm3
Flash Point: 392.9 °C
Enthalpy of Vaporization: 106.01 kJ/mol
Boiling Point: 726 °C at 760 mmHg
Vapour Pressure of Colchicine (CAS NO.64-86-8): 6.21E-21 mmHg at 25 °C

Uses

Colchicine(64-86-8) is used as an antimitotic agent that disrupts microtubles by binding to tubulin and preventing its polymerization. Stimulates the intrinsic GTPase activity of tubulin. Induces apoptosis in several normal and tumor cell lines and activates the JNK/SAPK signal.

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
bird - wild	LD50	oral	31600ug/kg (31.6mg/kg)		Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
cat	LD50	intravenous	250ug/kg (0.25mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: NAUSEA OR VOMITING	Journal of Pharmacology and Experimental Therapeutics. Vol. 106, Pg. 261, 1952.
cat	LDLo	oral	125ug/kg (0.125mg/kg)		"Principles of Insect Chemosterilization," Labrecque, G.C., and C.N. Smith, eds., New York, Appleton-Century-Crofts, 1968Vol. -, Pg. 315, 1968.
cat	LDLo	subcutaneous	500ug/kg (0.5mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1337, 1935.
child	TDLo	parenteral	2400ug/kg (2.4mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Veterinary and Human Toxicology. Vol. 37, Pg. 366, 1995.
dog	LDLo	oral	125ug/kg (0.125mg/kg)		"Principles of Insect Chemosterilization," Labrecque, G.C., and C.N. Smith, eds., New York, Appleton-Century-Crofts, 1968Vol. -, Pg. 315, 1968.
dog	LDLo	subcutaneous	571ug/kg (0.571mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1337, 1935.
dog	LDLo	unreported	5mg/kg (5mg/kg)		Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 27, Pg. 119, 1890.
gerbil	LD50	intraperitoneal	90mg/kg (90mg/kg)		Medicina et Pharmacologia Experimentalis. Vol. 17, Pg. 323, 1967.
guinea pig	LD50	intraperitoneal	500ug/kg (0.5mg/kg)		Medicina Experimentalis. Vol. 6, Pg. 101, 1962.
guinea pig	LDLo	oral	12500ug/kg (12.5mg/kg)	LIVER: OTHER CHANGES BLOOD: CHANGES IN SPLEEN BLOOD: OTHER CHANGES	Virchows Archiv fuer Pathologische, Anatomie und Physiologie, und fuer Klinische Medizin. Vol. 320, Pg. 93, 1951.
hamster	LD50	intraperitoneal	7300ug/kg (7.3mg/kg)		Medicina Experimentalis. Vol. 6, Pg. 101, 1962.
human	LDLo	intravenous	129ug/kg (0.129mg/kg)	VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION VASCULAR: SHOCK GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Human Toxicology. Vol. 2, Pg. 169, 1983.
human	LDLo	oral	86ug/kg (0.086mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA GASTROINTESTINAL: OTHER CHANGES	"Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 184, 1969.
human	TDLo	parenteral	710ug/kg (0.71mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION GASTROINTESTINAL: NAUSEA OR VOMITING	Archives of Internal Medicine. Vol. 137, Pg. 394, 1977.
man	LDLo	intravenous	143ug/kg/5D-I (0.143mg/kg)	BLOOD: APLASTIC ANEMIA MUSCULOSKELETAL: OTHER CHANGES	New England Journal of Medicine. Vol. 309, Pg. 310, 1983.
man	LDLo	oral	11mg/kg (11mg/kg)	LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Canadian Medical Association Journal. Vol. 138, Pg. 335, 1988.
man	TDLo	oral	400ug/kg (0.4mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"	Critical Care Medicine. Vol. 7, Pg. 278, 1979.
man	TDLo	oral	12514ug/kg/2Y (12.514mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS	New England Journal of Medicine. Vol. 316, Pg. 1562, 1987.
mouse	LD50	intramuscular	1197ug/kg (1.197mg/kg)		Journal of Medicinal Chemistry. Vol. 24, Pg. 257, 1981.
mouse	LD50	intraperitoneal	1600ug/kg (1.6mg/kg)		Journal of Medicinal Chemistry. Vol. 28, Pg. 1204, 1985.
mouse	LD50	intravenous	1700ug/kg (1.7mg/kg)		Drugs in Japan Vol. 6, Pg. 280, 1982.
mouse	LD50	oral	5886ug/kg (5.886mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	subcutaneous	1200ug/kg (1.2mg/kg)		Drugs in Japan Vol. 6, Pg. 280, 1982.
pigeon	LDLo	unreported	30mg/kg (30mg/kg)		Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 27, Pg. 119, 1890.
quail	LD50	oral	42mg/kg (42mg/kg)		Journal of Reproduction and Fertility. Vol. 48, Pg. 371, 1976.
rabbit	LDLo	intravenous	3mg/kg (3mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 67, Pg. 768, 1909.
rabbit	LDLo	oral	50mg/kg (50mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 67, Pg. 768, 1909.
rabbit	LDLo	subcutaneous	5mg/kg (5mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 67, Pg. 768, 1909.
rat	LD50	intravenous	1600ug/kg (1.6mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Toxicology and Applied Pharmacology. Vol. 13, Pg. 50, 1968.
rat	LDLo	intracrebral	1mg/kg (1mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: EXCITEMENT BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 109, Pg. 386, 1957.
rat	LDLo	intraperitoneal	1400ug/kg (1.4mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS MUSCULOSKELETAL: OTHER CHANGES GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Archives of Neurology Vol. 24, Pg. 72, 1971.
rat	LDLo	parenteral	1000ug/kg (1mg/kg)		Farmaco, Edizione Scientifica. Vol. 15, Pg. 533, 1960.
rat	LDLo	subcutaneous	4mg/kg (4mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 84, Pg. 257, 1950.
rat	LDLo	unreported	1mg/kg (1mg/kg)		"Principles of Insect Chemosterilization," Labrecque, G.C., and C.N. Smith, eds., New York, Appleton-Century-Crofts, 1968Vol. -, Pg. 315, 1968.
women	LDLo	intravenous	360ug/kg/6D (0.36mg/kg)	KIDNEY, URETER, AND BLADDER: OTHER CHANGES BLOOD: HEMORRHAGE	Nouvelle Presse Medicale. Vol. 9, Pg. 1587, 1980.
women	LDLo	oral	600ug/kg (0.6mg/kg)	CARDIAC: OTHER CHANGES BLOOD: APLASTIC ANEMIA	American Journal of Emergency Medicine. Vol. 16, Pg. 603, 1998.
women	LDLo	oral	3mg/kg (3mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Japanese Journal of Toxicology. Vol. 12, Pg. 337, 1999.
women	LDLo	oral	8360ug/kg (8.36mg/kg)	CARDIAC: OTHER CHANGES KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Journal of Analytical Toxicology. Vol. 4, Pg. 153, 1980.
women	TDLo	oral	320ug/kg (0.32mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Lancet. Vol. 2, Pg. 1271, 1987.
women	TDLo	oral	510ug/kg (0.51mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: APLASTIC ANEMIA	Human & Experimental Toxicology. Vol. 16, Pg. 229, 1997.
women	TDLo	oral	960ug/kg (0.96mg/kg)	CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP	New England Journal of Medicine. Vol. 322, Pg. 642, 1995.
women	TDLo	oral	1mg/kg (1mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP BLOOD: LEUKOPENIA	Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 71, 1995.
women	TDLo	oral	4368ug/kg/26W (4.368mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Neurology. Vol. 41, Pg. 943, 1991.

Consensus Reports

EPA Extremely Hazardous Substances List. EPA Genetic Toxicology Program. Reported in EPA TSCA Inventory.

Safety Profile

A human poison by ingestion and intravenous routes. Poison experimentally by most routes. Human systemic effects: aplastic anemia, blood pressure depression, body temperature decrease, changes in kidney tubules, dyspnea, flaccid paralysis without anesthesia, gastrointestinal effects, kidney damage and hemorrhaging, muscle contraction or spasticity, muscle weakness, nausea or vomiting, respiratory stimulation, and somnolence. An experimental teratogen. Experimental reproductive effects. A severe eye irritant. Human mutation data reported. Inhibits the formation of microtubules and thus impairs cell division. When heated to decomposition it emits toxic fumes of NO_x.
Hazard Codes: Very T+, Toxic T
Risk Statements: 26/28
R26/28:Very toxic by inhalation and if swallowed.
Safety Statements: 13-45
S13:Keep away from food, drink and animal foodstuffs.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: UN 1544 6.1/PG 1
WGK Germany: 3
RTECS: GH0700000
HazardClass: 6.1
PackingGroup: I

Specification

Colchicine (CAS NO.64-86-8), its Synonyms are 7-alpha-H-Colchicine ; 7alphaH-Colchicine ; AI3-31149 ; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (S)- ; Benzo(a)heptalen-9(5H)-one, 7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxy- ; Acetamide, N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- ; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (S)- . It is odorless or nearly odorless pale yellow needles or powder that darkens on exposure to light.